Uveal melanoma medical therapy: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
Line 20: | Line 20: | ||
*** Ipilimumab + radioembolization | *** Ipilimumab + radioembolization | ||
*** Ipilimumab + nivolumab +radioembolization | *** Ipilimumab + nivolumab +radioembolization | ||
** TILs | ** TILs (tumor-infiltrating lymphocytes) | ||
** T cell redirection | ** T cell redirection | ||
** Antibody–drug conjugate | ** Antibody–drug conjugate | ||
*** Glembatumumab vedotin | *** Glembatumumab vedotin | ||
* Targeted therapy | * Targeted therapy | ||
** PKC/MEK | ** PKC (protein kinase c)/ MEK (Methyl Ethyl Ketone) | ||
*** AEB071 + BYL719 | *** AEB071 + BYL719 | ||
*** Intermittent selumetinib | *** Intermittent selumetinib | ||
Line 34: | Line 34: | ||
*** Cabozantinib versus temozolomide/ dacarbazine | *** Cabozantinib versus temozolomide/ dacarbazine | ||
** Epigenetic therapy | ** Epigenetic therapy | ||
*** HDAC inhibition | *** HDAC (histone deacetylase) inhibition | ||
**** Vorinostat | **** Vorinostat | ||
**** Pembrolizumab + entinostat (PEMDAC) | **** Pembrolizumab + entinostat (PEMDAC) | ||
*** BET inhibition | *** BET (bromodomain and extra-terminal motif) inhibition | ||
** Liver-directed therapy | ** Liver-directed therapy | ||
*** IHP | *** IHP (isolated hepatic perfusion) | ||
*** PHP | *** PHP ( <br /> | ||
== References == | == References == |
Revision as of 03:15, 16 August 2019
Uveal melanoma Microchapters |
Diagnosis |
---|
Treatment |
Case Studies |
Uveal melanoma medical therapy On the Web |
American Roentgen Ray Society Images of Uveal melanoma medical therapy |
Risk calculators and risk factors for Uveal melanoma medical therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Fahimeh Shojaei, M.D., Simrat Sarai, M.D. [2]
Overview
Medical Therapy
Pharmacologic medical therapy is recommended among patients with metastatic disease:
- Chemotherapy
- Dacarbazine
- Temozolomide
- Cisplatin
- Treosulfan
- Fotemustine
- Immunotherapy
- Checkpoint blockade
- Pembrolizumab
- Ipilimumab + nivolumab
- Ipilimumab + nivolumab
- Ipilimumab + radioembolization
- Ipilimumab + nivolumab +radioembolization
- TILs (tumor-infiltrating lymphocytes)
- T cell redirection
- Antibody–drug conjugate
- Glembatumumab vedotin
- Checkpoint blockade
- Targeted therapy
- PKC (protein kinase c)/ MEK (Methyl Ethyl Ketone)
- AEB071 + BYL719
- Intermittent selumetinib
- Selumetinib +/– paclitaxel
- Binimetinib + AEB071
- Multikinase inhibition
- Sorafenib (STREAM)
- Cabozantinib versus temozolomide/ dacarbazine
- Epigenetic therapy
- HDAC (histone deacetylase) inhibition
- Vorinostat
- Pembrolizumab + entinostat (PEMDAC)
- BET (bromodomain and extra-terminal motif) inhibition
- HDAC (histone deacetylase) inhibition
- Liver-directed therapy
- IHP (isolated hepatic perfusion)
- PHP (
- PKC (protein kinase c)/ MEK (Methyl Ethyl Ketone)